Clinical Trials Logo

Severe Chronic Plaque Psoriasis clinical trials

View clinical trials related to Severe Chronic Plaque Psoriasis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05637515 Completed - Clinical trials for Severe Chronic Plaque Psoriasis

Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity

Start date: November 21, 2022
Phase: Phase 3
Study type: Interventional

Hulio is a monoclonal antibody currently approved as a biosimilar to European Union approved and United States (US)-Licensed Humira. This is a multicenter, randomized blinded, parallel group, interchangeability study in subjects with moderate to severe chronic plaque psoriasis, undergoing repeated switches between Humira and Hulio. The study is designed to confirm the pharmacokinetic equivalence of alternating between the use of Humira and Hulio and, Humira without such alternation or switch, in accordance with the US Food and Drug Administration Guidance for Industry, Considerations in Demonstrating Interchangeability with a Reference Product. The study will also assess safety, efficacy and immunogenicity between these two groups.

NCT ID: NCT04123795 Recruiting - Clinical trials for Moderate Chronic Plaque Psoriasis

A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)

CIMcare
Start date: January 21, 2020
Phase: Phase 3
Study type: Interventional

The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.